Common Stock, $0.01 par value
- Symbol
- KPRX
- Exchange
- NASDAQ
- Classification
- COMMON
Current Report · Items 7.01, 9.01 · 8-K
Kiora Pharmaceuticals, Inc.
Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On June 18, 2026, the Company issued a press release announcing preclinical data on its novel ion channel modulator platform, which significantly suppressed seizure-associated electrophysiological activity in an ex vivo temporal lobe epilepsy model.…
Company context
Kiora Pharmaceuticals is a clinical-stage biotechnology company developing therapies for retinal disease. The Company targets critical pathways underlying retinal diseases using small molecules designed to slow, stop or restore vision loss. KIO-301 is being developed initially for retinitis pigmentosa, with potential expansion into choroideremia and Stargardt disease. KIO-104 is being developed for macular edema associated with retinal inflammation.
Current securities
Recent company filings
- Entry into a Material Definitive Agreement · Regulation FD DisclosureOct 29, 2026
- SCHEDULE 13G - filed by Baselake Partners, LP regarding KIORA PHARMACEUTICALS INCSep 17, 2026
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD DisclosureSep 8, 2026
- Entry into a Material Definitive Agreement · Regulation FD DisclosureAug 19, 2026
- SCHEDULE 13G/A - filed by Nantahala Capital Management, LLC regarding KIORA PHARMACEUTICALS INCAug 14, 2026
Registered securities in this filing
KIORA PHARMACEUTICALS, INC. · 8-K · Filed 2026-06-18
Disclosure sections
Item 7.01Item 7.01 - Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure.
On June 18, 2026, the Company issued a press release announcing preclinical data on its novel ion channel modulator platform, which significantly suppressed seizure-associated electrophysiological activity in an ex vivo temporal lobe epilepsy model. The findings were presented in a poster at the Epilepsy Foundation Pipeline Conference taking place June 18-19, 2026, in Leesburg, VA. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information furnished herein, including Exhibit 99.1, is not deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section. This information will not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent that the registrant specifically incorporates them by reference.
Filed exhibits (1)
EX-99.1 2 ex991-pressreleasejune1820.htm EX-99.1 Document Exhibit 99.1 Kiora Pharmaceuticals Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Preclinical Epilepsy Model Data Presented at Epilepsy Foundation Pipeline Conference Demonstrated Significant Reduction in Epileptiform Activity The findings were reported at The Epilepsy Foundation Pipeline Conference taking place June 18-19, 2026 KIO-300 is the active pharmaceutical ingredient of KIO-301, Kiora’s ongoing Phase 2 clinical program in vision restoration in patients with gene mutation-agnostic Retinitis Pigmentosa ENCINITAS, CA - June 18, 2026 -- Kiora Pharmaceuticals (NASDAQ: KPRX) today announced preclinical data showing that KIO-300, part of the company’s novel ion channel modulator platform, significantly suppressed seizure-associated electrophysiological activity in an ex vivo temporal lobe epilepsy (TLE) model. The findings were presented in a poster at the Epilepsy Foundation Pipeline Conference taking place June 18-19, 2026, in Leesburg, VA. "These data reinforce the broad therapeutic potential of our ion channel modulator platform and suggest potential utility beyond ophthalmology,"…
Open exhibit ↗